Our work not only elucidates the molecular mechanisms underlying lenvatinib resistance but also demonstrates that targeting IGF2BP3 with siRNA‐loaded liposomes can resensitize resistant HCC cells to lenvatinib in vivo, suggesting a promising approach for clinical intervention. The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.